nelarabine (506U78)

10/24/2016 - "The combination with the pan PI3K inhibitor ZSTK-474 was the most effective in inhibiting the growth of T-ALL cells and was synergistic in decreasing cell survival and inducing apoptosis in nelarabine-resistant T-ALL cells. "
06/01/2011 - "The safety, tolerability, pharmacokinetics and efficacy of nelarabine were evaluated in adult and pediatric patients with relapsed or refractory T-ALL/T-LBL. "
10/18/2023 - "We review the medicinal biology of nelarabine, its evaluation through decades of clinical studies, its dose-limited adverse effects, and its areas of highest impact in the treatment of T-ALL/LLy. "
06/30/2023 - "Based on phase I and II trials in children and adults, single-agent nelarabine is approved for treatment of patients with R/R T-ALL/LBL, with the major adverse effect being central and peripheral neurotoxicity. "
01/01/2019 - "Although nelarabine is the only agent approved specifically for T-ALL, recent studies have identified a variety of genetic alterations and signaling pathways that are critical in its pathogenesis. "

07/01/2009 - "Nelarabine induced complete remission in an adult with refractory T-lineage acute lymphoblastic leukemia: A case report and review of the literature."
07/01/2006 - "This review presents a new compound, nelarabine, that has shown efficacy in treating patients with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma."
10/01/2017 - "Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study."
06/30/2023 - "Nelarabine: When, Where and How to Use it When Treating T-cell Acute Lymphoblastic Leukemia."
01/01/2023 - "Central nervous system neurotoxicity associated with nelarabine in T-cell acute lymphoblastic leukemia."

03/01/2008 - "Phase I trial of nelarabine in indolent leukemias."
01/01/2022 - "These data demonstrate that dNTP homeostasis governs leukemia maintenance, and a combination of DUSP inhibition and nelarabine represents a therapeutic strategy."
01/01/2022 - "There were no differences between the parental and nelarabine-resistant leukemia cells in the methylation status of the promoter region of the dCK gene. "
12/01/2013 - "Nelarabine is more cytotoxic in T-lineage than in B-lineage leukemias. "
07/01/2006 - "Nelarabine use in leukemias."

05/20/2005 - "Nelarabine is active as a single agent in recurrent T-cell leukemia, with a response rate more than 50% in first bone marrow relapse. "
05/20/2005 - "Further studies are planned to determine whether the addition of nelarabine to front-line therapy for T-cell leukemia in children will improve survival."
12/01/2006 - "We used low dose clofarabine and induced a remission in a patient who relapsed in the skin and marrow after allogeneic transplant and was refractory to nelarabine and report a near complete response, suggesting significant activity for low intermittent dose clofarabine in patients with relapsed T-cell leukemias."
01/01/1999 - "2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine (GW506U78), a prodrug of arabinosylguanine (ara-G), is effective in T-cell leukemias. "

05/20/2005 - "Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies."
12/01/2010 - "After being first synthesized in the late 1970s and receiving FDA approval in 2005, the appropriate use of nelarabine for refractory hematologic malignancies is still being elucidated. "
11/01/1998 - "Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response."
02/18/2009 - "This article reviews the pharmacology, mechanism of action, and pharmacokinetic properties of nelarabine, as well as nelarabine's clinical efficacy in T-ALL, T-LBL, and other hematologic malignancies. "
09/01/2007 - "Also reviewed are nelarabine's clinical efficacy in T-ALL, T-LBL, and other hematologic malignancies; its toxicity profile, dosage, and administration; and areas of ongoing and future research. "